INTERNATIONAL SCIENTIFIC RESEARCH AND INNOVATION CONGRESS -II
INVESTIGATION OF THE EFFECTS OF SILYMARIN ON DOCETAXELINDUCED HEART DAMAGE
Docetaxel (DTX) is a chemotherapeutic agent frequently used in different types of cancer such as head, neck, lung, breast and stomach cancer. In addition to its therapeutic properties, it has side effects such as cardiotoxicity. Silymarin (SLM) is a flavanoid-derived antioxidant with well-known antioxidant properties. The aim of the presented study was to investigate the effects of SLM on DTX-induced cardiotoxicity. A total of 35 rats were used in the study and were divided into 5 groups of 7 rats each. Group I (Control group), group II (SLM group), group III (DTX group), group IV (DTX + SLM25), group V (DTX + SLM50). Administrations continued for 7 days. DTX-induced cardiotoxicity and the effect of SLM were evaluated by examining serum markers of cardiac function, cardiac tissue antioxidant enzymes, oxidative stress markers and histology.As a result of the analysis of the heart tissues taken at the end of the study, it was determined that DTX administration increased MDA levels and decreased SOD, CAT, GPx activities and GSH levels. In addition, cardiac markers LDH and CK-MB were also found to increase with DTX administration. It was determined that SLM administration together with DTX showed antioxidant effect by decreasing MDA levels and increasing SOD, CAT, GPx activities and GSH levels and was successful in protecting the cell from the harmful effect of DTX. DTX administration in rat hearts caused histopathological changes, while SLM regulated these deleterious effects. As a result, it was determined that DTX-induced increased oxidative stress in rats was decreased by SLM administration and the damage that may occur in cells was prevented and SLM administration would be beneficial on DTX-induced cardiotoxicity.
